Piper Sandler began coverage on shares of Albireo Pharma (NASDAQ:ALBO) in a research note published on Thursday, BenzingaRatingsTable reports. The brokerage issued an overweight rating and a $45.00 price target on the biopharmaceutical company’s stock.
Several other brokerages have also issued reports on ALBO. Robert W. Baird began coverage on shares of Albireo Pharma in a report on Wednesday, June 24th. They set an outperform rating and a $52.00 price objective on the stock. Needham & Company LLC reissued a buy rating and issued a $50.00 price target on shares of Albireo Pharma in a research report on Tuesday, July 28th. Zacks Investment Research raised Albireo Pharma from a hold rating to a buy rating and set a $28.00 price objective on the stock in a research report on Monday, July 13th. BidaskClub downgraded shares of Albireo Pharma from a buy rating to a hold rating in a report on Thursday, July 2nd. Finally, HC Wainwright increased their price target on shares of Albireo Pharma from $62.00 to $64.00 and gave the company a buy rating in a research report on Thursday, July 16th. They noted that the move was a valuation call. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Albireo Pharma has an average rating of Buy and a consensus price target of $48.29.
Shares of ALBO stock opened at $28.26 on Thursday. Albireo Pharma has a twelve month low of $11.26 and a twelve month high of $31.50. The stock has a fifty day simple moving average of $26.30 and a two-hundred day simple moving average of $23.14.
Albireo Pharma (NASDAQ:ALBO) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($2.23) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.39) by ($0.84). The business had revenue of $1.55 million during the quarter, compared to analysts’ expectations of $1.19 million. Albireo Pharma had a negative return on equity of 72.82% and a negative net margin of 730.55%. As a group, equities analysts forecast that Albireo Pharma will post -6.96 EPS for the current year.
A number of institutional investors have recently added to or reduced their stakes in ALBO. Federated Hermes Inc. boosted its holdings in Albireo Pharma by 33.1% in the first quarter. Federated Hermes Inc. now owns 1,913,190 shares of the biopharmaceutical company’s stock worth $31,319,000 after acquiring an additional 476,190 shares in the last quarter. Chicago Capital LLC raised its position in shares of Albireo Pharma by 181.2% in the 1st quarter. Chicago Capital LLC now owns 492,878 shares of the biopharmaceutical company’s stock valued at $8,068,000 after purchasing an additional 317,589 shares during the last quarter. Perceptive Advisors LLC boosted its stake in Albireo Pharma by 15.0% in the 1st quarter. Perceptive Advisors LLC now owns 1,960,139 shares of the biopharmaceutical company’s stock worth $31,931,000 after purchasing an additional 255,809 shares in the last quarter. ArrowMark Colorado Holdings LLC grew its position in Albireo Pharma by 12.1% during the 1st quarter. ArrowMark Colorado Holdings LLC now owns 972,372 shares of the biopharmaceutical company’s stock worth $15,918,000 after purchasing an additional 105,322 shares during the last quarter. Finally, Prosight Management LP grew its position in Albireo Pharma by 33.7% during the 1st quarter. Prosight Management LP now owns 330,407 shares of the biopharmaceutical company’s stock worth $5,409,000 after purchasing an additional 83,229 shares during the last quarter. Institutional investors own 69.69% of the company’s stock.
About Albireo Pharma
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Further Reading: NASDAQ
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.